Research areas of PMI
Research- and Technology Fields (RTFs)
The ten Research and Technology Fields (RTFs) cover the most important technology platforms and fundamental research areas. They deal with aspects such as sequencing, model systems, biobanks, bioinformatics and data management. At the same time, they support other cluster members and are essential to their research.
Overview: Research- and Technology Fields (RTF) of PMI
- RTF I: Genomic diversity in chronic inflammatory diseases
- RTF II: Evolution and ecology of microbes
- RTF III: Individualized Cellular Models and Epigenetic Signatures of Inflammation
- RTF IV: Experimental Models of Inflammation
- RTF V: Clinical and Nutritional Metabolomics
- RTV VI: Sequence-based Profiling
- RTV VII: Multiscale Imaging
- RTV VIII: Theoretical Models of Inflammation
- RTF IX: Ethics, Epistemology, Communication and Economics
- RTF X: General Patient Access and CCIM
Target Innovation Projects (TIs)
The Target Innovation Projects (TIs) are four preclinical projects which are characterized by their high-risk and particularly innovative technology components. The goal is to subsequently implement these preclinical projects into clinical care.
Overview: Target Innovation Projects of PMI
Clinical Demonstrators (CDs)
In five Clinical Demonstrators (CDs), clinical trials are prepared which investigate the benefits and the applicability of precision medicine in inflammation. The main goal is to confirm principles clinically in patients, which have previously been discovered in preclinical experiments in the laboratory (proof-of-principle). The focus of the CDs is on unmet clinical needs, for which the cluster members have already developed a potential diagnostic tool or therapeutic principle during the previous cluster, which is supported by strong preclinical data.
Overview: „Clinical Demonstrators“ (CDs) of PMI
- CD-1: Individual Management – Prospective Cohorts from the CCIM for Definition of Disease Control
- CD-2: Tryptophan Metabolism and Inflammation
- CD-3: Individualized Antibiotic Therapy of Chronic Lung Infections
- CD-4: Advanced Optical in vivo Imaging in Patients
- CD-5: T Regulatory Cell-targeted Therapy Using Low-dose IL-2
